Who
Christopher Bowden
Director
Company insider
Files Form 4 as: Director, Bicara Therapeutics; Director, Alaunos Therapeutics; Chief Medical Officer, Agios Pharmaceuticals; Director, Viridian Therapeutics.
In numbers
- Trades disclosed
- 144
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $13.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 31 May 2014
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,475 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,475 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,746 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | TCRT Alaunos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Jun 2021filed 22 Jun 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,885 at $0.00 | filing |
| 18 Jun 2021filed 22 Jun 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —46,608 at $0.00 | filing |
| 18 Jun 2021filed 22 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $75K1,885 at $39.76 | filing |
| 18 Jun 2021filed 22 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.3M46,608 at $50.40 | filing |
| 18 Jun 2021filed 22 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.9M48,493 at $60.11 | filing |
| 17 Jun 2021filed 21 Jun 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,502 at $0.00 | filing |
| 17 Jun 2021filed 21 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $99K2,502 at $39.76 | filing |
| 17 Jun 2021filed 21 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $150K2,502 at $60.02 | filing |
| 10 Jun 2021filed 11 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $829K20,853 at $39.76 | filing |
| 10 Jun 2021filed 11 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.3M20,853 at $60.06 | filing |
| 10 Jun 2021filed 11 Jun 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,853 at $0.00 | filing |
| 9 Jun 2021filed 11 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $284K7,149 at $39.76 | filing |
| 9 Jun 2021filed 11 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $430K7,149 at $60.16 | filing |
| 9 Jun 2021filed 11 Jun 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,149 at $0.00 | filing |
| 8 Jun 2021filed 9 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $265K6,675 at $39.76 | filing |
News
Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Christopher Bowden; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.